Rybrevant 350mg injection contains the active substance Amivantamab. It is an antineoplastic drug that belongs to the class of medications called bispecific antibodies. It is used to treat a type of cancer called non-small cell lung cancer (NSCLC) that spreads to other parts of the body and has certain changes in a gene called EGFR. It is also used if it cannot be removed by surgery and has worsened during or after treatment with other anticancer medications.  

Do not take this injection if you are allergic to amivantamab or any other ingredients of this medicine. Inform your physician if you have suffered from inflammation of your lungs or any other lung conditions before initiating the therapy. Report to your physician if you face any symptoms of sudden difficulty in breathing, cough, or fever that may suggest inflammation of the lungs. Rybrevant 350mg injection is not recommended for children or young people below 18 years of age.  

Inform your physician if you have kidney problems, liver or lung problems before initiating the therapy. The common side effects of Rybrevant 350mg injection are rash, nail inflammation, musculoskeletal pain, shortness of breath, nausea, fatigue, swelling, inflamed and sore mouth, cough, constipation, and vomiting. This medicine may cause harm to the fetus hence use effective contraception during the treatment.

• Non-small cell lung cancer (NSCLC)

Rybrevant 350mg injection is an epidermal growth factor receptor (EGFR), and mesenchymal-epithelial transition factor (MET) targeted bispecific antibody that has been designed to recognize and attach to specific targets in the body. It targets two proteins found in cancer cells. It works by attaching to these proteins and may help to slow or stop your lung cancer from growing. It may also reduce the size of the tumor. 

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, recent vaccinations, nutritional and vitamin supplements, and herbal products. Certain medications may interact with Rybrevant 350mg injection and reduce its effectiveness by causing undesirable side effects. 

• Store Rybrevant 350mg injection in the refrigerator (2°C to 8°C)
• Do not freeze
• keep the injection away from the reach of children and pets.
• If you have missed any dosing appointments, inform your doctor and schedule immediately.

It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein) for several hours. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors. 

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. 

 Common 

• Swelling in the face, hands, and feet
• Inflammation in the nails
• Constipation
• Nausea, vomiting
• Inflamed and sore mouth
• Musculoskeletal pain
• Cough
• Shortness of breath
• Tiredness 

Serious 

• Severe rashes in the skin
• Eye pain and infection
• Inflammation of the lungs
• Infusion reactions

To reduce skin problems, limit sun exposure during and for 2 months after treatment, wear protective clothing, and apply sunscreen and moisturizers that are alcohol-free regularly on your skin and nails while taking this medicine. Contact your doctor or nurse immediately if you have eye pain or vision problems. Consult your doctor before using contact lenses when you are taking this medicine. Do not breastfeed during the treatment and for 3 months after the last dose. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy. 

1. Rybrevant (amivantamab) 50mg/mL concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc). www.medicines.org.uk. [revised on 2021] [cited 2023 Apr 6]. Available from: https://www.medicines.org.uk/emc/product/13084/pil
2. HIGHLIGHTS OF PRESCRIBING INFORMATION - amivantamab. [revised on 2021] [cited 2023 Apr 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf
3. Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study. Journal of Clinical Oncology [revised on 2021 Aug 2] [cited 2023 Apr 6];39(30):JCO.21.00662. Available from: https://pubmed.ncbi.nlm.nih.gov/34339292/